Shenzhen New Industries Biomedical Engineering Co. Ltd. Class A

Shenzhen New Industries Biomedical Engineering Co. Ltd. Class A

SSZSE:300832
62.90
CNY
+0.19
(+0.30%)
2.30EPS
21.89P/E
39.58BMarket Cap
Mar 31Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.87
0.8
1.06
1.31
1.62
1.97
2.39
2.93
3.25
3.88
5
5.77
5.82
6.18
Basic EPS, GAAP
0.7
0.37
0.36
0.64
0.76
0.99
1.1
1.25
1.24
1.69
2.11
2.33
2.06
2.3
Free Cash Flow per Basic Share
-0.02
0.17
0.27
- -
0.49
0.59
0.72
0.96
0.55
0.71
1.4
1.17
1.54
- -
Dividend per Share
0.06
0.03
0.06
0.08
0.26
0.14
- -
0.82
0.53
0.6
0.7
1
1.3
1.19
Book Value per Share
1.88
3.03
1.45
2.02
2.52
3.36
4.46
6.13
7.13
8.14
9.6
10.92
11.64
11.96
Tangible Book Value per Share
1.85
3
1.37
1.93
2.44
3.28
4.31
6.01
7.01
7.92
9.39
10.6
11.34
11.67
Basic Weighted Avg Shares
202
685
693
704
704
704
704
750
784
785
785
786
786
785
Sales/Revenue/Turnover
378
545
732
923
1,141
1,384
1,682
2,195
2,545
3,047
3,930
4,535
4,577
4,850
Operating Margin (%)
43.03
50.91
35.61
52.38
55.26
55.59
51.58
48.95
42.71
44.9
45.37
43.78
39.49
43.99
Depreciation Expense
4
6
23
16
36
40
53
79
97
116
154
186
202
- -
Net Income, GAAP
141
253
249
452
538
694
773
939
974
1,328
1,654
1,828
1,620
1,806
Effective Tax Rate (%)
14.25
14.79
14.44
14.52
14.52
14.02
14.01
14.37
14.25
11.54
12.65
12.65
12.67
12.99
Profit Margin (%)
37.36
46.38
34.05
48.96
47.19
50.16
45.95
42.79
38.25
43.58
42.08
40.32
35.4
37.24
Working Capital
275
338
664
1,047
1,196
1,602
2,177
3,630
3,989
4,238
4,473
4,147
5,060
5,655
LT Debt
51
- -
- -
- -
- -
- -
- -
1
1
1
3
3
2
1
Total Equity
379
611
1,023
1,419
1,772
2,366
3,139
4,804
5,612
6,399
7,544
8,577
9,145
9,400
Return on Invested Capital (%)
38.93
42.78
27.4
34.18
32.68
32.86
27.81
23.46
18.59
22.07
23.62
22.75
18.48
20.38
Return on Capital (%)
41.64
48.53
30.5
36.99
33.73
33.59
28.07
23.64
18.69
22.11
23.71
22.68
18.28
20.39
Return on Common Equity (%)
45.06
51.12
30.5
36.99
33.73
33.54
28.07
23.65
18.7
22.11
23.72
22.68
18.29
20.39

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
786
786
786
Market Capitalization
38,555
33,000
39,577

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,988
5,760
6,356
Cash, Cash Equivalents & STI
2,423
2,133
2,739
Accounts Receivable, Net
999
995
918
Inventories
1,081
1,048
1,111
Total Current Liabilities
568
631
701
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.19%
13.81%
6.63%
Free Cash Flow
- -
20.26%
32.02%
Net Income, GAAP
22.61%
12.75%
-11.39%
Sales/Revenue/Turnover
20.41%
16.19%
0.91%
Total Cash Common Dividend
- -
14.1%
30.01%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,021
1,190
1,203
1,121
4,535
2025
1,125
1,060
- -
1,149
4,577
2026
1,129
1,292
1,280
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.54
0.61
0.61
0.57
2.33
2025
0.56
0.42
- -
0.53
2.06
2026
0.56
0.54
0.67
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
- -
- -
1
2025
- -
1.3
- -
- -
1.3
2026
- -
1.19
- -
- -
- -

Company Description

CEO
Wei Rao
Full Time Employees
2,785
Sector
Health technology
Industry
Medical specialties
Address
New Industry Biological Building Shenzhen GD China 518118
IPO Date
May 12, 2020
Website
snibe.com
Business
Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) develops, manufactures and sells clinical laboratory instruments and in vitro diagnostic reagents for hospitals and testing institutions worldwide. The company offers chemiluminescence immunoassay analyzers including the MAGLUMI X8, X6, X3, X10 and M series; biochemistry and electrolyte analyzers such as Biossays C10, C8, 240 Plus and E6 Plus; integrated systems like Biolumi CX8; lab automation solutions including the open fully automatic sample processing system SATLARS T8 and SATLARS-TCA; molecular diagnostic analyzers such as Molecision R8, S6, MP-32 and MP-96 with associated test menus; hemostasis analyzers like Hemolumi H6; and point-of-care testing products, supported by extensive chemiluminescence, biochemistry and molecular diagnostic reagent portfolios covering up to 260 CLIA parameters for applications in gonads, thyroid, glucose metabolism, kidney function, infectious diseases and more. SNIBE operates through segments encompassing instruments and supporting software, reagents, and accessories; it serves markets in Asia, Europe, America, Africa and beyond from its headquarters at No.23 Jinxiu East Road, Pingshan District, Shenzhen, China, where it was founded in 1995 and employs approximately 2,841 staff across a 55,000 square meter modern production facility. Recent developments include the acquisition of land use rights in Shenzhen's Pingshan District for 80 million yuan covering 37,831.7 square meters to construct the No. 5 Snibe building as a new headquarters facility; participation in major 2025 trade shows such as MEDICA, ADLM and Euromedlab to showcase diagnostic solutions; the SATLARS T8 winning the iF DESIGN AWARD 2025; approval of 2024 dividends payable in May 2025; and sustained R&D investment exceeding 15% of revenue to drive molecular diagnostics and international expansion particularly in Southeast Asia.